Physician profile
Jennifer Conner
NPI 1083677397
$794.42
in general payments reported to CMS, 2019-2025
23 companies · $16.84 in 2025
The $16.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.56 · 2020: $28.59 · 2021: $216 · 2022: $319 · 2023: $179 · 2025: $16.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $166.23 | 2022-2023 | |
| Abbvie INC. | $118.34 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.79 | 2021-2023 | Xifaxan |
| Pfizer INC. | $64.28 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $47.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2021-2022 | |
| Amarin Pharma, INC. | $29.13 | 2020-2021 | |
| Novo Nordisk INC | $28.26 | 2021-2023 | Saxenda, Wegovy |
| Biogen, INC. | $19.75 | 2021 | |
| Almirall LLC | $19.13 | 2019 | |
| Seqirus USA INC | $18.80 | 2022 | |
| Abbott Laboratories | $17.70 | 2022 | |
| Array Biopharma INC | $16.84 | 2025 | Braftovi |
| Biohaven Pharmaceutical Holding Company LTD. | $14.73 | 2022 | |
| Eisai INC. | $13.96 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.43 | 2022 | |
| Amgen INC. | $13.31 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.50 | 2021 | |
| Kaleo, INC. | $12.17 | 2021 | |
| Glaxosmithkline, LLC. | $12.02 | 2022 | |
| Merck Sharp & Dohme LLC | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.